Starling Oncology, Inc. (STLN) Cash Flow Statement
Starling Oncology, Inc. (STLN) generated $328000 of operating cash flow over the twelve months to 2026-06-30, spent $3.6M on capital expenditure and had free cash flow of -$3.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
STLNStarling Oncology, Inc.Follow STLN — free
—
Price chart with a free account
- Market cap
- 683.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -32.7 | -61.8 | -36.3 | -26.5 | -24.6 | 0.3 | |
| Capital expenditure | 2.8 | 5.5 | 4.6 | 3.8 | 3.2 | -3.6 | |
| Free cash flow | -35.5 | -67.3 | -40.9 | -30.3 | -27.8 | -3.3 | |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Share repurchases | — | 9.0 | 1.0 | 0.0 | — | — | |
| Stock-based compensation | 24.5 | 27.7 | 17.8 | 11.2 | 4.6 | — |
USD millions · SEC XBRL
Starling Oncology, Inc. — questions
- What is Starling Oncology, Inc.'s operating cash flow?
- $328000 over the twelve months to 2026-06-30.
- How much does Starling Oncology, Inc. spend on capital expenditure?
- $3.6M over the twelve months to 2026-06-30.
- What is Starling Oncology, Inc.'s free cash flow?
- -$3.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Starling Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.